Lactic acid bacterium agent for improving lipid metabolism

Patent metadata

Field	Value
Publication number	US-9468657-B2
Application number	US-201113702742-A
Country	US
Kind code	B2
Filing date	Jun 8, 2011
Priority date	Jun 8, 2010
Publication date	Oct 18, 2016
Grant date	Oct 18, 2016

Abstract

This invention provides an effective means or method for improving lipid metabolism, and a means or method for treatment or prevention of diseases or disorders associated with the lipid metabolism disorder. Specifically, this invention relates to an agent for improving the lipid metabolism comprising, as active ingredients, broken cells of a lactic acid bacterium, and to a method for enhancing an effect of a lactic acid bacterium for improving the lipid metabolism comprising a step of breaking the lactic acid bacterium.

First claim

The invention claimed is:

1. A method for enhancing an effect of a lactic acid bacterium on lipid metabolism in a subject, comprising:
(a) breaking the lactic acid bacterium to produce a composition consisting essentially of as the active ingredient broken cells of the lactic acid bacterium by grinding, milling, enzyme treatment, chemical treatment or lysis, such that the long diameter of a broken cell of the lactic acid bacterium is 90% or less of the long diameter of the lactic acid bacterium before breaking; (b) orally administering the composition to a vertebrate animal subject; and (c) enhancing lipid metabolism in the subject.

2. The method according to claim 1 , wherein the broken cells of lactic acid bacterium are obtained via physical disruption, chemical treatment, or lysis.

3. The method according to claim 1 , wherein the lactic acid bacterium is at least one or at least two bacteria selected from the group consisting of Lactobacillus amylovorus strain CP1563 , Lactobacillus amylovorus strain CP1562, and Lactobacillus gasseri strain CP3238.

4. The method according to claim 1 , wherein the lactic acid bacterium is broken such that the long diameter of a broken cell of the bacterium is 70% or less of that of before breaking.

5. The method according to claim 1 , wherein the vertebrate animal subject is at risk of having a lipid metabolism-associated disease or disorder.

6. The method according to claim 5 , wherein the lipid metabolism-associated disease or disorder is arteriosclerosis, hyperlipidemia, fatty liver, diabetes, myocardial infarct, or cerebral infarction.

7. The method according to claim 1 , wherein the composition comprising broken cells of the lactic acid bacterium is formulated into a powder, granules, tablet, capsule or a liquid formulation prior to administering the composition to the mammal.

8. The method of claim 1 , wherein the composition comprising broken cells of the lactic acid bacterium is formulated into a food or a drink prior to administering the composition to the mammal.

9. The method of claim 1 , wherein the vertebrate animal subject is a human.

10. The method of claim 1 , wherein the lactic acid bacterium is Lactobacillus or Bifidobacterium.

11. The method of claim 1 , wherein the lactic acid bacterium is Lactobacillus amylovorus or Lactobacillus gasseri.

12. A method for enhancing an effect of a lactic acid bacterium on lipid metabolism in a subject, comprising:
(a) breaking the lactic acid bacterium by grinding, milling, enzyme treatment, chemical treatment or lysis, such that the diameter of a broken cell of the lactic acid bacterium is 2.5 μm or less of the diameter of the lactic acid bacterium before breaking, to produce a composition consisting essentially of as the active ingredient broken cells of the lactic acid,
(b) orally administering the composition to a vertebrate animal subject; and
(c) enhancing lipid metabolism in the subject.

13. The method of claim 12 , wherein the diameter of a broken cell of the bacterium is 2 μm or less.

14. A method for enhancing an effect of a lactic acid bacterium on lipid metabolism in a subject, comprising:
(a) breaking the lactic acid bacterium by grinding, milling, enzyme treatment, chemical treatment or lysis, such that the long diameter of a broken cell of the lactic acid bacterium is 90% or less of the long diameter of the lactic acid bacterium before breaking, to produce a composition consisting essentially of as the active ingredient broken cells of the lactic acid bacterium, and wherein the composition consisting essentially of as the active ingredient broken cells of the lactic acid bacterium is more effective than intact lactic acid bacterium at: (i) lowering at least one selected from the group consisting of the levels of total cholesterol, LDL-cholesterol, neutral fat, arteriosclerosis index, and visceral fat, or (ii) elevating a level of at least one of HDL-cholesterol and adiponectin, when administered to a mammal;
(b) orally administering the composition to a vertebrate animal subject; and
(c) enhancing lipid metabolism in the subject.

15. A method for enhancing an effect of a lactic acid bacterium on lipid metabolism in a subject, comprising:
(a) breaking the lactic acid bacterium by grinding, milling, enzyme treatment, chemical treatment or lysis, such that the long diameter of a broken cell of the lactic acid bacterium is 90% or less of the long diameter of the lactic acid bacterium before breaking, to produce a composition consisting essentially of as the active ingredient broken cells of the lactic acid bacterium, wherein the composition consisting essentially of as the active ingredient broken cells of the lactic acid bacterium is more effective than intact lactic acid bacterium for treating a lipid metabolism- associated disease or disorder in a mammal;
(b) orally administering the composition to a vertebrate animal subject; and
(c) enhancing lipid metabolism in the subject.

16. A method for enhancing an effect of a lactic acid bacterium on lipid metabolism in a subject, comprising:
(a) breaking the lactic acid bacterium to produce a composition comprising broken cells of the lactic acid bacterium, wherein the lactic acid bacterium is broken such that the average long diameter of a broken cell of the bacterium is 0% to 90% of the diameter of the lactic acid bacterium before breaking, and wherein the composition comprising broken cells of the lactic acid bacterium is more effective than intact lactic acid bacterium for treating arteriosclerosis, hyperlipidemia, fatty liver, diabetes, myocardial infarct, or cerebral infarction in a mammal; and
(b) orally administering the composition to a vertebrate animal subject, wherein the effect of the lactic acid bacterium on lipid metabolism in the subject is enhanced compared to a composition comprising cells of a lactic acid bacterium that are not broken.

17. A method for enhancing an effect of a lactic acid bacterium on lipid metabolism in a subject, comprising:
orally administering to a subject a composition consisting essentially of as the active ingredient broken cells of the lactic acid bacterium, wherein the lactic acid bacterium was broken by grinding, milling, enzyme treatment, chemical treatment or lysis, such that the long diameter of a broken cell of the lactic acid bacterium is 90% or less of the long diameter of the lactic acid bacterium before breaking.

18. A method for enhancing an effect of a lactic acid bacterium on lipid metabolism in a subject, comprising:
orally administering to a subject a composition consisting essentially of as the active ingredient broken cells of the lactic acid bacterium, wherein the lactic acid bacterium was broken by grinding, milling, enzyme treatment, chemical treatment or lysis, such that the diameter of a broken cell of the lactic acid bacterium is 2.5 μm or less of the diameter of the lactic acid bacterium before breaking.

Assignees

• Nakamura Futoshi
• Ishida Yu
• Fujiwara Shigeru
• Asahi Group Holdings Ltd

Inventors

• Nakamura Futoshi
• Ishida Yu
• Fujiwara Shigeru

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title